A New Prognostic Index in Young Breast Cancer Patients | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2022]

Author(s):

1. Hacer Demir: Department of Medical Oncology, Afyon Health Sciences University School of Medicine,Afyonkarahisar,Turkey

2. Ayse Demirci: Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey

3. Saliha Karagoz Eren: Department of General Surgery, Kayseri City Hospital,Kayseri,Turkey

4. Ismail Beypinar: Department of Medical Oncology, Eski_ehir City Hospital,Eski_ehir,Turkey

5. Sena Ece Davarc: Department of General Surgery, Kayseri City Hospital,Kayseri,Turkey

6. Meltem Baykara: Department of Medical Oncology, Afyon Health Sciences University School of Medicine,Afyonkarahisar,Turkey

Abstract:

Objective:To evaluate the prognostic role of pan immune-in ammation value (PIV) in young breast cancer patients. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Afyon University of Health Sciences, School of Medicine Hospital, Turkey, between January 2010 and December 2020. Methodology: Patients who were under the age of 40 years at the time of diagnosis were included. Patients characteristics and disease parameters were recorded. PIV was calculated according to (neutrophil x platelet x monocyte/lymphocytei,.e. NxPxM/L) formula. Since a cut-o value with max sensitivity and speci city could not be obtained with ROC analysis, the median value of PIV was used as cut-o value. The relationship between PIV and pathological parameters was evaluated by ROC curves. The Kaplan-Meier method was used for OS and the log-rank test was used to evaluate the survival di erences between the two groups, according to the optimal cut-o point. Results: Based on the PIV cut-o value of 121 (49.8%) patients were in the low PIV and 122 (50.2%) patients were in the high PIV group. The patients in the high PIV group had a statistically signi cantly more advanced AJCC stage, and were younger patients. In the survival analysis, it was observed that the survival was worse in the high PIV group but this di erence did not reach statistical signi cance (p=0.112). Conclusion: Higher PIV levels at the time of diagnosis can be another prognostic marker. However, to clarify the PIV prognostic value, it needs to be validated in larger, multi-centre prospective clinical studies.

Page(s): 86-91

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 1, Year: 2022

Keywords:

Breast Cancer , prognosis , Pan immunein ammation value PIV , Young women

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views